Prior Authorization Review Panel
MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: Keystone First	Submission Date:1/1/2026
Policy Number: CCP.1275	Effective Date:4/4/2017 Revision Date:12/1/2025
Policy Name: Actigraphy	

Type of Submission:

☐ New Policy	☒ Prior Authorization Policy
☒ Revised Policy*	☐ Base Policy
☐ Annual Review- no revisions	☒ Experimental/Investigational Policy
	☐ Statewide PDL
	☐ Other:

*All revisions to the policy must be highlighted using track changes throughout the document.

Please provide any clarifying information for the policy below:

Name of Authorized Individual (Please type or print): Manni Sethi, MD, MBA, CHCQM	Signature of Authorized Individual: 

Actigraphy

Clinical Policy ID: CCP.1275

Recent review date: 12/2025

Next review date: 4/2027

Policy contains: Actigraphy, circadian rhythm sleep disorders, polysomnography.

Keystone First- CHIP has developed clinical policies to assist with making coverage determinations. Keystone First- CHIP's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Keystone First- CHIP, on a case by case basis, when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Keystone First- CHIP's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Keystone First- CHIP's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Keystone First- CHIP will update its clinical policies as necessary. Keystone First- CHIP's clinical policies are not guarantees of payment.

Coverage policy

Actigraphy is investigational/not clinically proven and, therefore, not medically necessary.

Limitations

No limitations were identified during the writing of this policy.

Alternative covered services

- Facility based polysomnogram.
- Multiple sleep latency test.
- Split-night sleep studies.
- Unattended home polysomnograms.

Background

Actigraphy is a method of continually measuring patterns of human rest and activity cycles (unit movements) through an actimetry sensor. The technique was first used in the 1960s. The three main types of this device are sleep actigraphs, activity actigraphs, and movement actigraphs. Improvements in actigraphy technology include piezoelectric sensors, lithium batteries, and digital data storage (Martin, 2011).

Since the 1990s, the predominant purpose for the device has been to monitor sleep behavior. Sleep actigraphs, which are worn on the non-dominant arm like a wristwatch, often for a week or more, are used for disorders like insomnia, circadian rhythm sleep disorders, sleepiness, and restless leg syndrome. Unlike polysomnography, actigraphs permit movement by the patient while data are recorded. Information can be transmitted to a computer

or can be analyzed in real time (Martin, 2011). Actigraphy offers a more convenient, less invasive, waterproof, and lower cost option to polysomnography. Data from actigraphy can cover multiple nights, while polysomnography is performed in a laboratory, usually for only one or two nights (Fekedulegn, 2020).

Actigraphy is also used to measure activity behavior. Activity actigraphs are worn like a pedometer around the waist. They are used for several days and evaluate activities while awake, plus calories burned. Activity actigraphs are preferable for measuring and assessing activities during waking hours rather than sleep.

A third type of actigraphy is used to measure human movement to determine problems with gait and other physical impairments. Movement actigraphs are larger than sleep or activity actigraphs and are worn on the dominant shoulder. These actigraphs are three-dimensional (the others are one-dimensional) and are used only for several hours at a time (John, 2012).

Several devices have received 510(k) regulatory approval as Class II worn activity devices. The devices are intended to monitor the activity associated with movement during sleep and can be used to analyze circadian rhythms and assess activity in any instance where quantifiable analysis of physical motion is desirable (U.S. Food and Drug Administration, 2023).

Findings

The totality of evidence regarding actigraphy demonstrates that while the technology offers a feasible, non-invasive method for estimating sleep parameters in real-world settings, it does not currently possess the diagnostic accuracy to replace polysomnography as the clinical standard. Systematic reviews and meta-analyses consistently indicate that although actigraphy exhibits high sensitivity in detecting sleep, it lacks the specificity required to distinguish motionless wakefulness from true sleep or to accurately classify sleep stages. Research highlights significant heterogeneity in device performance, scoring algorithms, and study protocols, limiting the ability to generalize findings across patient populations. Consequently, professional guidelines offer only conditional recommendations for its use in specific sleep disorders. Recent data regarding its application in pediatric and psychiatric cohorts confirm that confounding factors and a lack of standardization preclude its acceptance as a medically necessary diagnostic alternative.

Guidelines

The primary clinical guidance for this technology comes from the American Academy of Sleep Medicine, which issued recommendations for the use of actigraphy to evaluate sleep disorders and circadian rhythm sleep-wake disorders. The Academy limited these recommendations to clinical-grade devices approved by the U.S. Food and Drug Administration, explicitly excluding consumer wearable devices or nonprescription devices directly marketed to consumers (Smith, 2018a). The guidelines provide one strong recommendation, which advises against using actigraphy in place of electromyography for the diagnosis of periodic limb movement disorder in adult and pediatric patients.

All other recommendations are graded as conditional, reflecting a low degree of certainty regarding outcomes and appropriateness for all patients. These conditional recommendations suggest using actigraphy to estimate sleep parameters in adult and pediatric patients with insomnia disorder or circadian rhythm sleep-wake disorder. Additionally, the Academy conditionally supports using the device to estimate total sleep time in adults with suspected insufficient sleep syndrome or suspected sleep-disordered breathing, provided it is integrated with home sleep apnea tests in the absence of alternative objective measurements. Finally, the guidelines suggest

using actigraphy to monitor total sleep time prior to testing with the Multiple Sleep Latency Test in patients with suspected central disorders of hypersomnolence (Smith, 2018a).

Meta-analyses

Quantitative syntheses of the literature generally demonstrate that while actigraphy provides more useful data than sleep logs alone, it consistently differs from the gold standard of polysomnography. A meta-analysis of 81 studies, which served as the basis for the American Academy of Sleep Medicine guidelines, found that actigraphy estimates correlated more closely with polysomnography than sleep logs in patients with insomnia, circadian rhythm disorders, and sleep-disordered breathing, provided validated algorithms and standardized scoring were used (Smith, 2018b). However, a separate meta-analysis of 96 studies involving 4,134 participants found significant discrepancies in measurement. Compared to polysomnography, actigraphy overestimated total sleep time by an average of 22.42 minutes and underestimated sleep onset latency by 7.70 minutes, with larger differences observed in adults with chronic conditions compared to healthy adults (Conley, 2019). Regarding specific pathologies, a meta-analysis of 14 studies on periodic limb movements noted that results were heterogeneous and required improvement before replacing polysomnography (Plante, 2014).

Recent meta-analyses have focused on specific clinical indications and pediatric feasibility. In the realm of mental health, a 2025 meta-analysis of 19 observational studies (N = 1,368) assessed sleep abnormalities in individuals at clinical high risk for psychosis and those with schizophrenia spectrum disorders. The study found that while actigraphy could detect increased total sleep time in schizophrenia spectrum disorders compared to healthy controls, the results were heavily confounded by medication effects, age, and gender, limiting clinical interpretability (Aronica, 2025). Regarding pediatric use, a 2025 meta-analysis of 135 studies covering 64,541 children demonstrated a high pooled adherence rate of 81.6%. Notably, this analysis found that adherence was significantly higher in children with neurodevelopmental or mental health diagnoses compared to undiagnosed peers, though variability across study contexts remained high (Morris, 2025).

Systematic reviews

Systematic reviews of the broader evidence base highlight that actigraphy possesses high sensitivity for detecting sleep but limited specificity for identifying wakefulness. A large review noted that specificity levels were consistently low, ranging from 26% to 77% in healthy subjects and 32% to 80% in patient groups, because the devices often fail to identify motionless wakefulness (de Zambotti, 2019). This limitation was reinforced by a 2024 review of eight studies (N = 1,139), which found that while actigraphy showed moderate accuracy in distinguishing wake from sleep, its ability to classify specific sleep stages such as light, deep, or rapid eye movement sleep was limited (Yuan, 2024).

In comparative studies of home-based measures, a review of 71 articles found that results for diagnosing insomnia were mixed, though findings were generally consistent for measuring sleep patterns in mental health disorders (Scott, 2020). Regarding prognosis in heart failure, a review of 17 studies (N = 2,759) found that while real-world measurement is feasible, the prognostic value of actigraphy varies depending on the specific physical activity parameter considered (Tan, 2019). Similarly, a review of 38 studies (N = 3,758) on depressive and bipolar disorders found discernible measurement patterns but concluded that further research linking results to disease severity is needed to establish clinical utility (Tazawa, 2019). Consensus from the International Biomarkers

Workshop in Sleep and Circadian Science further indicates that wearable devices still lack validation against gold standard measurements (Depner, 2020).

Evidence regarding the use of actigraphy in pediatric populations reveals variable accuracy depending on the clinical condition and the specific device used. In newborns (N = 40) admitted to neonatal intensive care, actigraphy showed accurate sleep-wake detection compared to polysomnography (Unno, 2021). Children with autism spectrum disorder (N = 26) also showed similar results between the two methods for most parameters (Yavuz-Kodat, 2019). However, significant discrepancies were noted in other pediatric groups. In children referred for snoring or enlarged tonsils (N = 56), actigraphy underestimated total sleep time by 31.5 minutes and sleep efficiency by 12.9% while overestimating wake after sleep onset by 56.1 minutes (Burkart, 2021).

Similarly, in children with attention deficit hyperactivity disorder (N = 48), the device underestimated sleep duration and efficiency compared to healthy controls (Waldon, 2016). Comparisons of specific devices found that while both the Actiwatch 2 [Manufacturer, City, State] and a fitness tracker showed high sensitivity in children (N = 17) and adolescents (N = 17), specificity was poor, particularly in adolescents (Pesonen, 2018). Additionally, in children treated for craniopharyngioma (N = 50), actigraphy differed from polysomnography by an average of 15 minutes for total sleep time (Niel, 2019).

In adult populations, the diagnostic utility of actigraphy is frequently compromised by disease-specific factors and demographic variables. Studies in sleep laboratory settings (N = 281) indicated that actigraphy overestimated sleep time in obstructive sleep apnea but underestimated it in narcolepsy (Alakuijala, 2021). Among adults with insomnia (N = 53), the device showed better detection rates for those with normal sleep duration compared to those with short sleep duration (Galbiati, 2021). Accuracy appears particularly low in older adults; one study of elderly males (N = 1,141) found actigraphy did not accurately predict sleep quality compared to polysomnography (Faerman, 2020).

Another study of older adults in a home setting (N = 46) reported a specificity of only 40% (Regalia, 2021). Agreement with polysomnography was also poor in patients with traumatic brain injuries (N = 227), where actigraphy underestimated sleep disruption (Zeitzer, 2020). In pregnant women (N = 78), differences in sleep measures were significant, with authors suggesting that specific scoring settings are required to improve accuracy in this population (Zhu, 2018). Finally, comparative results were similar for participants with chronic insomnia disorder (N = 35) but discordant for those with sleep-disordered breathing (N = 31), limiting generalizability (Choi, 2017).

In 2025, we reviewed a systematic review and meta-analysis, which found that actigraphy detected sleep abnormalities in schizophrenia spectrum disorders but was significantly confounded by medication effects (Aronica, 2025), and a systematic review and meta-analysis demonstrating generally high device adherence in school-aged children, particularly those with health diagnoses (Morris, 2025); no policy changes were warranted.

References

On November 18, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “actigraphy,” “sleep studies,” “obstructive sleep apnea,” and “polysomnography.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Alakuijala A, Sarkanen T, Jokela T, Partinen M. Accuracy of actigraphy compared to concomitant ambulatory polysomnography in narcolepsy and other sleep disorders. *Front Neurol*. 2021;12:629709. Doi: 10.3389/fneur.2021.629709.

Aronica R, Ostinelli EG, Austin C, et al. Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analysis. *BMJ Ment Health*. 2025;28(1):e301337. Doi: 10.1136/bmjment-2024-301337.

Burkart S, Beets MW, Armstrong B, et al. Comparison of multichannel and single-channel wrist-based devices with polysomnography to measure sleep in children and adolescents. *J Clin Sleep Med*. 2021;17(4):645-652. Doi: 10.5664/jcsm.8980.

Choi SJ, Kang M, Sung MJ, Joo EY. Discordant sleep parameters among actigraphy, polysomnography, and perceived sleep in patients with sleep-disordered breathing in comparison with patients with chronic insomnia disorder. *Sleep Breath*. 2017;21(4):837-843. Doi: 10.1007/s11325-017-1514-5.

Conley S, Knies A, Batten J, et al. Agreement between actigraphic and polysomnographic measures of sleep in adults with and without chronic conditions: A systematic review and meta-analysis. *Sleep Med Rev*. 2019;46:151-160. Doi: 10.1016/j.smrv.2019.05.001.

Depner CM, Cheng PC, Devine JK, et al. Wearable technologies for developing sleep and circadian biomarkers: A summary of workshop discussions. *Sleep*. 2020;43(2):zsz254. Doi:10.1093/sleep/zsz254.

de Zambotti M, Cellini N, Goldstone A, Colrain IM, Baker FC. Wearable sleep technology in clinical and research settings. *Med Sci Sports Exerc*. 2019;51(7):1538-1557. Doi: 10.1249/MSS.0000000000001947.

Faerman A, Kaplan KA, Zeitzer JM, et al. Subjective sleep quality is poorly associated with actigraphy and heart rate measures in community-dwelling older men. *Sleep Med*. 2020;73:154-161. Doi: 10.1016/j.sleep.2020.04.012.

Fekedulegn D, Andrew ME, Shi M, Violanti JM, Knox S, Innes KE. Actigraphy-based assessment of sleep parameters. *Ann Work Exposures and Health*. 2020;64(4):350-367. Doi: 10.1093/annweh/wxaa007.

Galbiati A, Sforza M, Leitner C, et al. The reliability of objective total sleep time in predicting the effectiveness of cognitive-behavioral therapy for insomnia. *Sleep Med*. 2021;82:43-46. Doi: 10.1016/j.sleep.2021.03.021.

John D, Freedson P. Actigraph and actical physical activity monitors: A peek under the hood. *Med Sci Sports Exerc*. 2012;44(1 Suppl 1): S86-S89. Doi: 10.1249/MSS.0b013e3182399f5e.

Martin JL, Hakim AD. Wrist actigraphy. *Chest*. 2011;139(6):1514-1527. Doi: 10.1378/chest.10-1872.

Morris AC, Seker A, Telesia L, et al. Adherence to actigraphic devices in elementary school–aged children: systematic review and meta-analysis. *J Med Internet Res*. 2025;27:e79718. Doi: 10.2196/79718

Niel K, LaRosa KN, Klages KL, et al. Actigraphy versus polysomnography to measure sleep in youth treated for craniopharyngioma. *Behav Sleep Med*. 2019:1-9. Doi: 10.1080/15402002.2019.1635133.

Pesonen AK, Kuula L. The validity of a new consumer-targeted wrist device in sleep measurement: An overnight comparison against polysomnography in children and adolescents. *J Clin Sleep Med*. 2018;14(4):585-591. Doi: 10.5664/jcsm.7050.

Plante DT. Leg actigraphy to quantify periodic limb movements of sleep: A systematic review and meta-analysis. *Sleep Med Rev*. 2014;18(5):425-434. Doi: 10.1016/j.smrv.2014.02.004.

Regalia G, Gerboni G, Migliorini M, et al. Sleep assessment by means of a wrist actigraphy-based algorithm: Agreement with polysomongraphy in an ambulatory study on older adults. *Chronobiol Int*. 2021;38(3):400-414. Doi: 10.1080/07420528.2020.1835942.

Scott H, Lack L, Lovato N. A systematic review of the accuracy of sleep wearable devices for estimating sleep onset. *Sleep Med Rev*. 2020;49:101227. Doi: 10.1016/j.smrv.2019.101227.

Smith MT, McCrae CS, Cheung J, et al. Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: An American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2018a;14(7):1231-1237. Doi: 10.5664/jcsm.7230.

Smith MT, McCrae CS, Cheung J, et al. Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: An American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med*. 2018b;14(7):1209-1230. Doi: 10.5664/jcsm.7228.

Tan MKH, Wong JKL, Bakrania K, et al. Can activity monitors predict outcomes in patients with heart failure? A systematic review. *Eur Heart J Qual Care Clin Outcomes*. 2019;5(1):11-21. Doi: 10.1093/ehjqcco/qcy038.

Tazawa Y, Wada M, Mitsukura Y, et al. Actigraphy for evaluation of mood disorders: A systematic review and meta-analysis. *J Affect Disord*. 2019;253:257-269. Doi: 10.1016/j.jad.2019.04.087.

Unno M, Morisaki T, Kinoshita M, et al. Validation of actigraphy in hospitalised newborn infants using video polysomnography. *J Sleep Res*. 2021;e13437. Doi: 10.1111/jsr.13437.

U.S. Food and Drug Administration. 510(k) Premarket Notification database searched using product code LEL. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Last updated October 23, 2023.

Waldon J, Bergum E, Gendron M, et al. Concordance of actigraphy with polysomnography in children with and without attention-deficit hyperactivity disorder. *J Sleep Res*. 2016;25(5):524-533. Doi: 10.1111/jsr.12402.

Yavuz-Kodat E, Reynaud E, Geoffray MM, et al. Validity of actigraphy compared to polysomnography for sleep assessment in children with Autism Spectrum Disorder. *Front Psychiatry*. 2019;10:551. Doi: 10.3389/fpsyt.2019.00551.

Yuan H, Hill EA, Kyle SD, Doherty A. A systematic review of the performance of actigraphy in measuring sleep stages. *J Sleep Res*. 2024;33(5):e14143. Doi:10.1111/jsr.14143.

Zeitzer JM, Hon F, Whyte J, et al. Coherence between sleep detection by actigraphy and polysomnography in a multi-center, inpatient cohort of individuals with traumatic brain injury. *PM R*. 2020;12(12):1205-1213. Doi: 10.1002/pmrj.12353.

Zhu B, Calvo RS, Wu L, et al. Objective sleep in pregnant women: A comparison of actigraphy and polysomnography. *Sleep Health*. 2018;4(5):390-396. Doi: 10.1016/j.sleh.2018/07.011.

Policy updates

11/2016: initial review date and clinical policy effective date: 4/2017

11/2017: Policy references updated.

11/2018: Policy references updated. Policy changed from medically necessary to investigational.

11/2019: Policy references updated. Policy ID changed to CCP.1275.

11/2020: Policy references updated.

11/2021: Policy references updated.

11/2022: Policy references updated.

12/2023: Policy references updated.

12/2024: Policy references updated.

12/2025: Policy references updated.